Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.
Institutional & Insider Ownership
79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by company insiders. Comparatively, 1.9% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Jasper Therapeutics and DBV Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jasper Therapeutics | 0 | 0 | 9 | 0 | 3.00 |
| DBV Technologies | 0 | 0 | 2 | 0 | 3.00 |
Earnings and Valuation
This table compares Jasper Therapeutics and DBV Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jasper Therapeutics | N/A | N/A | -$64.46 million | ($4.86) | -0.92 |
| DBV Technologies | $15.73 million | 8.11 | -$72.73 million | ($4.50) | -1.38 |
Jasper Therapeutics has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Jasper Therapeutics and DBV Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jasper Therapeutics | N/A | -67.64% | -58.53% |
| DBV Technologies | -815.73% | -106.07% | -76.17% |
Volatility and Risk
Jasper Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Summary
Jasper Therapeutics beats DBV Technologies on 10 of the 12 factors compared between the two stocks.
About Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
